Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02383212 · ClinicalTrials.gov registry record · Phase 1

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

A Phase 1 study of Advanced Cancer and Advanced Malignancies, sponsored by Regeneron Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
398
Enrollment target
20
Study locations

NCT02383212 is a Phase 1 study of Advanced Cancer and Advanced Malignancies that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 398 participants, above the 243-participant average among 122 other Advanced Cancer trials with a reported enrollment target (64% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02383212, a Phase 1 study of Advanced Cancer and Advanced Malignancies, has completed, sponsored by Regeneron Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
398 participants
Enrollment target
20
Study locations

Study Summary

This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.

Conditions Studied

Advanced Cancer Advanced Malignancies

Interventions

  • DRUG Cyclophosphamide
  • DRUG Carboplatin
  • DRUG Docetaxel
  • DRUG Cemiplimab
  • RADIATION Hypofractionated radiotherapy

Study Locations (20)

Arizona

  • Banner MD Anderson Cancer Center - Gilbert
  • Western Regional Medical Center - Goodyear
  • Mayo Clinic - Phoenix
  • University of Arizona Cancer Center - Tucson

California

  • City of Hope National Medical Center - Duarte
  • The Angeles Clinic and Research Institute - Los Angeles
  • Ronald Reagan UCLA Medical Center - Los Angeles
  • Stanford University - Stanford

Colorado

  • Sarah Cannon Research Institute at HealthONE - Denver

Connecticut

  • Norwalk Hospital - Norwalk

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Florida

  • H Lee Moffitt Cancer Center and Research Institute - Tampa

Georgia

  • Winship Cancer Institute, Emory University - Atlanta

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 398 participants
Start Date 2015-02-02
Est. Completion 2019-11-18
Phase Phase 1

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02383212

The ClinicalTrials.gov registry entry for NCT02383212 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 398 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 243-participant average among 122 other Advanced Cancer trials with a reported enrollment target (64% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT02383212 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Arizona, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT02383212 about?

NCT02383212 is a clinical study titled "Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies". This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.

What is the current status of trial NCT02383212?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 398 participants. The study started on 2015-02-02. Estimated completion is 2019-11-18.

What conditions does trial NCT02383212 study?

This clinical trial studies the following conditions: Advanced Cancer, Advanced Malignancies.

What interventions are being tested in trial NCT02383212?

The interventions under investigation include: Cyclophosphamide (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), Cemiplimab (DRUG), Hypofractionated radiotherapy (RADIATION).

Who is sponsoring clinical trial NCT02383212?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02383212 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Cancer

All registered trials for this condition

Advanced Malignancies

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.